The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $35.11, a high ...

Fintel reports that on April 10, 2025, Mizuho initiated coverage of Tandem Diabetes Care (NasdaqGM:TNDM) with a Neutral ...

Tandem Diabetes Care, Inc. TNDM shares soared 7.6% in the last trading session to close at $17.61. The move was backed by solid volume with far more shares changing hands than in a normal session.

Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

The doctors say barriers continue to prevent access to AID, including costs. Such barriers exemplify “the implicit ...

CMO Jordan Pinsker said Tandem hopes to expand Medicare coverage of its automated insulin delivery systems with results of a ...

Mizuho initiated coverage of Tandem Diabetes (TNDM) with a Neutral rating and $20 price target The firm’s neutral stance reflects both the ...

Tandem Diabetes (TNDM) announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company’s advanced ...

In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s Mobi pump, designed for discretion and simplicity, and the ...

slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq ... Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type ...